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Background: The Nrf2 transcription factor is a 
master regulator of cellular antioxidant defense 
systems. 
Results: We identified novel Nrf2 activators in 
keratinocytes with low toxicity and strong UV-
protective potential. 
Conclusion: Chemical library screening combined 
with virtual screening is a potent strategy to 
identify optimized Nrf2 activators. 
Significance: Our new Nrf2 activators are 
potential lead compounds for the development of 
drugs for skin protection under stress conditions. 
 
SUMMARY  
Nuclear factor erythroid derived 2-related 
factor 2  (Nrf2) is a master regulator of cellular 
antioxidant defense systems, and activation of 
this transcription factor is a promising strategy 
for protection of skin and other organs from 
environmental insults. To identify efficient Nrf2 
activators in keratinocytes we combined a 
chemical library screen with computer-based 
virtual screening. Among fourteen novel Nrf2 
activators, the most potent compound, a 
nitrophenyl derivative of 2-chloro-5-nitro-N-
phenyl-benzamide, was characterized with 
regard to its molecular mechanism of action. 
This compound induced the expression of 
cytoprotective genes in keratinocytes isolated 
from wild-type, but not from Nrf2-deficient 
mice. Most importantly, it showed low toxicity 
and protected primary human keratinocytes 
from UVB-induced cell death. Therefore, it 
represents a potential lead compound for the 
development of drugs for skin protection under 
stress conditions. Our study demonstrates that 
chemical library screening combined with 
advanced computational similarity searching is 
a powerful strategy for identification of 
bioactive compounds, and points toward an 
innovative therapeutic approach against UVB-
induced skin damage. 
 
INTRODUCTION  
Ultraviolet (UV) irradiation, gamma 
irradiation or various toxic or irritant chemicals 
challenge the skin, the outermost surface of our 
body. Many of these insults cause oxidative stress 
through enhanced production of reactive oxygen 
species (ROS). This results in cell damage and 
inflammation, and also contributes to skin aging 
and even neoplastic transformation (1, 2). One of 
the most important regulators in the defense 
against oxidative stress is the transcription factor 
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nuclear factor erythroid derived 2-related factor 2 
(Nrf2). It is ubiquitously expressed, and 
particularly high expression levels are seen in 
epithelial cells, including keratinocytes of the skin 
(3). Nrf2 belongs to the Cap’n’Collar family of 
transcription factors, which also includes the 
related Nrf1 and Nrf3 proteins, as well as p45NF-
E2, Bach1 and Bach2 (4, 5). Under basal 
conditions Nrf2 is predominantly present in the 
cytoplasm where it is anchored to the actin-
binding protein Keap1 that mediates its 
degradation through the ubiquitin-proteasome 
pathway. Electrophilic substances can activate 
Nrf2 through modification of Keap1 cysteine 
residues (6). This results in the stabilization of 
Nrf2 and its accumulation in the nucleus (7). In 
addition, it has been suggested that ROS can 
activate certain kinases, which in turn 
phosphorylate Nrf2, resulting in its stabilization 
and activation (8). However, we could not verify 
the latter mechanism in keratinocytes, and it may 
therefore be cell-type specific (9). Upon nuclear 
translocation, Nrf2 dimerizes with small Maf 
proteins or other leucine zipper proteins and binds 
as a heterodimer to cis-acting elements in the 
promoters of its target genes, designated as 
antioxidant response elements (AREs). The core 
consensus sequence of an ARE was characterized 
by deletion analysis and is defined as 5’-
TGACnnnGC-3’ (10).  
Genes that are regulated by Nrf2 encode, 
among others, proteins that help to control the 
cellular redox state and protect the cell against 
oxidative damage or toxic chemicals. These 
proteins include several ROS detoxifying enzymes 
and other antioxidant proteins, including 
NAD(P)H dehydrogenase quinone 1 (NQO1), 
different glutathione S-transferases (GST), the 
regulatory and catalytic subunits of the glutathione 
biosynthesis enzyme γ-glutamylcysteine ligase (γ-
GCL; GCLM and GCLC), peroxiredoxins (PRDX) 
1 and 6, and heme oxygenase-1 (HO-1). Studies 
with knockout mice highlighted the important role 
of Nrf2 in the cellular stress response. Nrf2-
deficient animals are more susceptible to diseases 
related to oxidative stress compared to their wild-
type littermates (11). In the skin, loss of Nrf2 
prolonged the inflammatory response after 
wounding (3). Most importantly, incidence and 
multiplicity of chemically-induced skin tumors 
were strongly enhanced in transgenic mice 
expressing a dominant-negative mutant of Nrf2 in 
keratinocytes (12) as well as in Nrf2 knockout 
mice (13). Since the basal activity was shown to 
mediate these protective effects (12), it was 
suggested that further activation of Nrf2 could be 
used for cancer prevention. Indeed, several 
preclinical and clinical studies with Nrf2-
activating compounds support this hypothesis (14, 
15). Furthermore, transgenic mice expressing a 
constitutively active (ca)Nrf2 mutant in 
keratinocytes were protected from UVB-induced 
apoptosis in the back skin epidermis. Expression 
of caNrf2 resulted in the activation of Nrf2 target 
genes and, therefore, reduced the levels of 
intracellular ROS in keratinocytes (16). 
Due to these cytoprotective functions of Nrf2 
in vivo, it is of major interest to identify Nrf2-
activating compounds in keratinocytes that can be 
exploited therapeutically to impede skin-damaging 
effects, e.g. of UV irradiation. One of the best-
characterized Nrf2 activators is the broccoli sprout 
component sulforaphane (SFN), which activates 
Nrf2 by chemical modification of highly reactive 
cysteine residues of Keap1 (17). Topical 
application of broccoli sprout extracts on SKH-1 
hairless mice strongly reduced the tumor 
multiplicity and total tumor burden in a UV-
induced skin carcinogenesis study (18). However, 
sulforaphane exerts Nrf2-independent effects, e.g. 
through direct regulation of glutathione levels (19, 
20), and we recently showed that long-term 
treatment of the skin with this compound causes 
an ichthyosis-like skin phenotype (21). In addition, 
a common feature of many cosmetic ingredients 
that cause skin sensitization is their capability to 
activate Nrf2 as shown in reporter gene assays 
with cultured cells (22). Therefore, it is desirable 
to identify and characterize novel Nrf2-activating 
compounds with high specificity and activity but 
low toxicity, which can be used for in vivo 
application. In this study we used a novel strategy 
to identify Nrf2 activating compounds - combining 
a chemical library screen with computer-based 
virtual screening. We identified novel and highly 
potent Nrf2-activating compounds in keratinocytes 
with a remarkable cytoprotective function. 
 
EXPERIMENTAL PROCEDURES 
Chemicals – Rosiglitazone, T0070907, compound 
1 (GW9662) and BADGE were from Enzo Life 
Sciences (Lausen, Switzerland). Compounds 
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identified by the virtual screen were obtained from 
Asinex (Rijswjk, The Netherlands), 
InterBioScreen (Moscow, Russia) or Specs 
(Wakefield, RI). Recombinant human Keap1 
protein was purchased from Origene (Rockville, 
MD). Forskolin was purchased from Sigma 
(Munich, Germany) and human tumor necrosis 
factor-alpha (TNF-α) was from PeproTech 
(Hamburg, Germany). 
Cell culture – Cells were cultured at 37 °C in a 
humid atmosphere containing 5 % CO2 (v/v). The 
immortalized, non-tumorigenic human HaCaT 
keratinocyte cell line was cultured in Dulbecco’s 
Modified Eagle Medium (DMEM) containing 10 
% fetal calf serum (FCS; Invitrogen, Paisley, UK) 
and 1 % penicillin/streptomycin.  
Spontaneously immortalized keratinocytes 
from Nrf2 knockout (23) mice and their wild-type 
littermates were obtained in our laboratory by 
serial passaging of primary cells. The latter were 
obtained from 3-day old wild-type and Nrf2 
knockout mice (3). While most cells became 
senescent upon multiple passaging, a few foci of 
immortalized cells appeared, which were further 
passaged. Cells were maintained in defined 
keratinocyte serum-free medium (dk-SFM) 
(Invitrogen) supplemented with 10 ng/ml 
epidermal growth factor, 10-10 M cholera toxin and 
1 % penicillin/streptomycin (all from Sigma).  
Primary human foreskin keratinocytes (HFK) 
were established from human foreskin obtained 
from the Department of Dermatology, University 
Hospital Zurich. They were cultured up to six 
passages in Keratinocyte-SFM supplied with 
epidermal growth factor and bovine pituitary 
extract (Invitrogen).   
Construction of ARE luciferase reporter 
plasmids – ARE luciferase reporter plasmids were 
generated using the pGL3-promoter vector 
(Promega, Madison, WI), which includes an SV40 
promoter upstream of the firefly luciferase gene. 
Double stranded oligonucleotides were 
synthesized containing a part of the promoter of 
the respective Nrf2 target gene, including the ARE 
(underlined). The different inserts are 1xARE-
mGclm (forward strand 5’-CCTGGAAGACAAT 
GACTAAGCAGAAAC-3’ and reverse strand 5’-
TCGAGTTTCTGCTTAGTCATTGTCTTCCAG
GAGCT-3’), 1xARE-ratNqo1 (forward strand 5’-
CTCTAGAGTCACAGTGACTTGGCAAAATCT
GAC-3’ and reverse strand TCGAGTCAGATTT 
TGCCAAGTCACTGTGACTCTAGAGAGCT-
3’) and 8xARE-mGclm (forward strand 5’-
CATGACTAAGCACCCATGACTAAGCACCC
ATGACTAAGCACCCATGACTAAGCACCCA
TGACTAAGCACCCATGACTAAGCACCCAT
GACTAAGCACCCATGACTAAGCACCCC-3’ 
and reverse strand 5’-TCGAGGGGTGCTTAGT 
CATGGGTGCTTAGTCATGGGTGCTTAGTCA
TGGGTGCTTAGTCATGGGTGCTTAGTCATG
GGTGCTTAGTCATGGGTGCTTAGTCATGGG
TGCTTAGTCATGAGCT-3’). The sequence was 
extended (bold) to generate 5’-terminal SacI and 
3’-terminal XhoI restriction sites. After annealing 
of the complementary oligonucleotides, the double 
stranded oligonucleotides were inserted into the 
pGL3 vector upstream of the SV40 promoter. In 
addition, a plasmid was generated with eight 
copies of the minimal functional ARE sequence 
present in the murine Gclm (ATGACTAAGCA) 
gene promoter. Each ARE copy was linked with 
the sequence 5’-CCC-3’ and 5’-GGG-3’ on the 
opposite strand to another copy. Oligonucleotide 
synthesis and sequencing of the final plasmids 
were performed by Microsynth (Balgach, 
Switzerland). Additional reporter plasmids with a 
nuclear factor-kappa B (NF-κB) binding site 
(pNF-κB-luc), a serum response element (SRE; 
pSRE-luc) or a cAMP response element (CRE; 
pCRE-luc) were obtained from Clontech 
(Mountain View, CA).  
Transient transfection and luciferase reporter 
assays – Transfection of HaCaT cells and 
immortalized mouse keratinocytes was performed 
with linear polyethyleneimine (Polysciences, 
Warrington, PA). Cells were plated at a density of 
2x105 cells/well in 12-well plates (Nunc, Roskilde, 
Denmark) and grown to 80 % confluency (24 h). 
After two washing steps with PBS, 1 ml Opti-
MEM I (Invitrogen) was added and the cells were 
co-transfected with 2 µg of the ARE luciferase 
reporter plasmid and 0.01 µg of the phRL-CMV 
Renilla luciferase vector plasmid (Promega) as an 
internal control for transfection efficiency when 
different reporter plasmids were compared. 3.8 µl 
of polyethyleneimine solution (1 mg/ml) was then 
added, the mixture was vortexed, incubated at 
room temperature for 15 min to allow complex 
formation and added to the cells. After 24 h the 
cells were washed with PBS and incubated with 
fresh culture medium containing tBHQ (Merck, 
Darmstadt, Germany), sulforaphane (Sigma) or 
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DMSO as negative control. Cells were harvested 
24 h later using Passive Lysis Buffer (Promega). 
Firefly and Renilla luciferase activities were 
measured in the lysates using the Dual-Luciferase 
Reporter Assay System kit (Promega) according to 
the manufacturer’s instructions. Luciferase activity 
was determined in a MicroLumatPlus LB96V 
luminometer (Berthold Technologies, Bad 
Wildbad, Germany). For the library screen and the 
validation of the screening results we seeded 9x106 
cells into 15 cm dishes and added a transfection 
mixture containing 90 µg pGL3-8xARE-mGclm 
reporter plasmid, 171 µl polyethyleneimine and 
4.2 ml 0.9 % (w/v) NaCl. Since all cells were 
transfected in the same plate with the same 
reporter plasmid, co-transfection with a Renilla 
luciferase plasmid was not performed in this case. 
Luciferase activity was measured by adding 
luciferase assay reagent consisting of 20 mM 
tricine, 2.67 mM MgSO4, 0.1 mM 
ethylenediaminetetraacetic acid, 33.3 mM 
dithiothreitol, 0.27 mM coenzyme A, 0.53 mM 
adenosine triphosphate (all from Sigma) and 0.47 
µM luciferin potassium salt (Synchem, Kassel, 
Germany), pH 7.8.   
Screening of a chemical library – The LOPAC 
library (Sigma), containing 1280 
pharmacologically active compounds, was used 
for the screen. All chemicals of this library are 
arranged in 96-well plates, dissolved in DMSO, 
and have a concentration of 10 mM. To generate 1 
mM stock plates aliquots of the compounds were 
diluted with DMSO in fresh 96-well tissue culture 
plates. HaCaT cells were transiently transfected 
with the reporter vector pGL3-8xARE-mGclm 
(see above). Cells were trypsinized 24 h after 
transfection and seeded into 96-well plates (25,000 
cells/well). 24 h later the medium was replaced by 
fresh growth medium and the cells were treated for 
24 h with 10 µM of the chemicals of the library. 
Afterwards cells were washed with PBS, lysed in 
Passive Lysis Buffer (Promega), and luciferase 
activity was measured as described above using 
the luciferase assay reagent.  
Screening compound library – For virtual 
screening we compiled a collection of 1,033,267 
compounds from selected commercial vendors: 
Specs Natural Products v08/2010, Specs Screening 
Collection v08/2010 (Specs, Delft, The 
Netherlands); Interbioscreen Natural Compound 
Library v08/2010, Interbioscreen Synthetic 
Compound Collection v08/2010 (Interbioscreen, 
Moscow, Russia); Asinex Gold v08/2010, Asinex 
Platinum v08/2010, Asinex Synergy v08/2010 
(Asinex, Moscow, Russia). All compounds were 
pre-processed using the ‘wash’ function (i.e., 
deprotonation of strong acids, protonation of 
strong bases) in the Molecular Operating 
Environment (MOE) software (The Chemical 
Computing Group Inc., Montreal, Canada). For 
each compound a single heuristic three-
dimensional conformation was generated with 
CORINA 3.46 (Molecular Networks, Erlangen, 
Germany) for autocorrelation (LIQUID) and graph 
(PoLiMorph) descriptor calculation. For ligand-
based virtual screening, we computed similarity 
values between queries and all screening pool 
compounds. We considered pool compounds as 
virtual hits if they were retrieved among the top 1 
% most similar compounds for both descriptors 
and among the top 100 compounds using the 
added rank of both methods for sorting. From the 
resulting virtual hit lists, we manually selected 
compounds for bioactivity determination. 
Quantitative Real-time RT-PCR (qRT-PCR) – 
RNA was isolated using the RNeasy Mini kit 
(Qiagen, Hilden, Germany) following the 
instructions of the manufacturer. cDNA was 
generated using the iScriptTMcDNA Synthesis Kit 
(Bio-Rad, Hercules, CA). Relative gene 
expression was determined using the Roche 
LightCycler 480 SYBR Green system (Roche, 
Rotkreuz, Switzerland). The following set of 
primers were used: mGclc-for  5’-AACAAGAAA 
CATCCGGCATC-3’ and mGclc-rev 5’-CGTAGC 
CTCGGTAAAATGGA-3’, mGclm-for 5’-
TCCCATGCAGTGGAGAAGAT-3’ and mGclm-
rev 5’-AGCTGTGCAACTCCAAGGAC-3’, 
mNqo1-for 5’-CTGGCCCATTCAGAGAAGAC-
3’ and mNqo1-rev 5’-GTCTGCAGCTTCCAGCT 
TCT-3’, mRps29-for 5’-GGTCACCAGCAGCTC 
TACTG-3’ and mRps29-rev 5’-GTCCAACTTAA 
TGAAGCCTATGTCC-3’, hGCLC-for 5’-GGAA 
GGAAGGTGTGTTTCCTGG-3’ and hGCLC-rev 
5’-ACTCCCTCATCCATCTGGCAA-3’,hGCLM-
for 5’-CCAGATGTCTTGGAATGCACTG-3’  
and hGCLM-rev 5’-AGGACTGAACAGGCCAT 
GTCA-3’, hNQO1-for 5’-GTGATATTCCAGTT 
CCCCCTGC-3’ and hNQO1-rev 5’-AAGCACTG 
CCTTCTTACTCCGG-3’, and hRPL27-for 5’-
TCACCTAATGCCCACAAGGTA-3’ and 
hRLP27-rev 5’-CCA CTTGTTCTTGCCTGTC 
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TT-3’. Each sample was analyzed in duplicates 
and the amplification of cDNA of the 
housekeeping genes mRps29 (murine) or hRPL27 
(human) was used for normalization.  
MTT and LDH assays – Human foreskin 
keratinocytes (HFK) were seeded in 24-well plates 
(45,000 cells/well) and cultured overnight. Cells 
were treated for 24 h with different concentrations 
of test compounds (1 µM - 100 µM). For the MTT 
assay the medium was supplemented with 100 µl 
of MTT solution (5 mg/ml in sterile PBS) (Sigma). 
After 2 h incubation, the supernatant was aspirated 
and the cells were lysed in 200 µl 40 mM 
HCl/isopropanol for 10 min at RT. The reaction 
was stopped by addition of an equal volume of 
water. The optical density was measured at 590 
nm. To measure LDH release the CytoTox 96® 
Non-Radioactive Cytotoxicity Assay kit 
(Promega) was used according to the 
manufacturer’s protocol.  
Mass spectrometry analysis of cysteine 
modification of Keap1 – Recombinant human 
Keap1 protein (6 pmol) was incubated with a five-
fold molar excess of test compound in a total 
volume of 100 µl in 50 mM Tris-HCl, pH8, 150 
mM NaCl for 3 h at room temperature. 
Subsequently, the protein was digested by addition 
of 10 ng of mass spectrometry grade trypsin 
(Promega) and incubated for 16 h at 37 °C. 
Peptides were cleaned up using µC18-ZipTip 
columns (Millipore) and analyzed on an LTQ-
Orbitrap XL ETD mass spectrometer (Thermo 
Fischer Scientific, Bremen, Germany) coupled to 
an Eksigent-Nano-HPLC system (Eksigent 
Technologies, Dublin (CA), USA). Solvent 
composition at the two channels was 0.2 % formic 
acid, 1 % acetonitrile for channel A and 0.2 % 
formic acid, 80 % acetonitrile for channel B. 
Peptides were loaded on a self-made tip column 
(75 µm x 80 mm) packed with reverse phase C18 
material (AQ, 3 µm, 200 Å, Bischoff GmbH, 
Leonberg, Germany) and eluted with a flow rate of 
200 nl per min by a gradient from 0 to 10 % of B 
in 5 min, 47 % B in 55 min, 97 % B in 58 min. 
Full-scan MS spectra (300-2000 m/z) were 
acquired with a resolution of 60,000 at 400 m/z 
after accumulation to a target value of 500,000. 
Collision induced dissociation (CID) MS/MS 
spectra were recorded in data dependent manner in 
the ion trap from the three most intense signals 
above a threshold of 500, using a normalized 
collision energy of 35 % and an activation time of 
30 ms. Charge state screening was enabled and 
singly charge states were rejected. Precursor 
masses already selected for MS/MS were excluded 
for further selection for 90 s and the exclusion 
window was set to 20 ppm. The size of the 
exclusion list was set to a maximum of 500 
entries. Peak lists were extracted from raw data 
files using Mascot Distiller (Matrix Science) and 
searched against a UniProtKB/Swiss-Prot database 
release 15.13 using the Mascot v2.3 search engine 
with the following parameters: Trypsin for enzyme 
specificity allowing up to one missed cleavage; 
oxidation (M, C), di- and trioxidation (C) and 
mass shifts at C corresponding to the test 
compound as variable modifications; parent mass 
error at 10 ppm, fragment mass error at 0.8 Da. 
Analysis of intracellular ROS levels – HFKs 
were seeded in 12-well plates and grown 
overnight. Medium was changed and cells were 
incubated with 100 µM 2’7’-dichloro-
dihydrofluorescein diacetate (H2DCFDA) 
(Invitrogen) for 30 min in the CO2 incubator. The 
cells were washed once with HEPES buffered salt 
solution (HBSS; 25 mM HEPES, 120 mM NaCl, 
5.4 mM KCl, 1.8 mM CaCl2, 25 mM NaHCO3, 15 
mM glucose, pH 7.4), and subsequently incubated 
in fresh medium with different concentrations of 
test compounds (1 µM - 100 µM). Fluorescence 
was measured after 0 - 24 h using a fluorescence 
multiwell plate reader (Spectramax M2, Molecular 
Devices, Ismaning, Germany) with excitation and 
emission wavelengths of 485 nm and 530 nm. 
UVB irradiation – HFKs were seeded in 12-
well plates (90,000 cells/well) and grown 
overnight. After treating the cells for 1 h, 4 h or 24 
h with 5 µM SFN, 50 µM compound 1, 50 µM 
compound 1a, or DMSO as control the medium 
was replaced by fresh growth medium. Cells were 
then irradiated with 50 mJ/cm2 UVB using a 
Medisun FH-54 lamp (Schulze & Böhm, Huerth, 
Germany) equipped with six UVB-TL/12 bulbs (9 
W each; Philipps, Amsterdam, Netherlands), 
which emit UVB light in the range of 280 to 315 
nm with a peak emission at 312 to 315 nm. 24 h 
later MTT or LDH assays were performed.  
Statistical analysis – Statistical analysis was 
performed using the PRISM software (Graph Pad 
Software Inc., La Jolla, CA). A two-way ANOVA 
analysis with Bonferroni post-test to compare 
multiple groups was performed. *P≤0.05, 
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**P≤0.005, ***P≤0.001. 
 
RESULTS 
Screening of a chemical library for new Nrf2 
activators – To identify novel Nrf2 activators in 
keratinocytes we performed a chemical library 
screen. For this purpose we first tested the 
efficiency of several AREs (Supplementary Table 
S1) to activate a luciferase reporter gene with a 
minimal promoter in the human HaCaT 
keratinocyte cell line. The ARE from the murine 
(m) Gclm gene was identified as particularly 
potent (data not shown) and was therefore chosen 
for further studies. Due to the high homology 
between murine and human Nrf2 (5), most mouse 
AREs, including the mGclm ARE, can be used to 
study Nrf2 activity in human cells. First, we 
generated a multimer with eight copies of the ARE 
(pGL3-8xARE-mGclm), which further enhanced 
the efficiency in the activation of a luciferase 
reporter gene compared to the monomeric ARE 
(Supplementary Fig.S1). This reporter gene 
construct was subsequently used to screen the 
Library of Pharmacologically Active Compounds 
(LOPAC1280 TM, Sigma-Aldrich), which comprises 
1280 bioactive, well-characterized compounds that 
act via 56 classes of pharmacological targets. 
HaCaT keratinocytes were transiently transfected 
with pGL3-8xARE-mGclm and treated for 24 h 
with the compounds from the library (assay 
concentration 10 µM each). The solvent DMSO 
was used as a negative control, and the known 
Nrf2 activators tert-butylhydrochinone (tBHQ) 
and SFN served as positive controls. Three 
independent screening rounds were conducted. A 
two-fold increase in luciferase activity was set as 
threshold for a positive hit. Forty-five hit 
compounds were discovered in at least one 
screening experiment. Six of them were positive in 
each screen, and seven were positive in two 
screens. These 13 putative Nrf2-activating 
substances were chosen for further analysis 
(compounds 1-13; Table 1). The 32 hit compounds 
appearing in only one of the three screening runs 
(Supplementary Table S2) were not further 
investigated.  
Three of the 13 hit compounds had been 
previously described as activators of Nrf2. These 
included iodoacetamide (24), parthenolide (25), 
and quercetin dehydrate (26). In addition, 3,4-
dichloroisocoumarin is structurally related to the 
known Nrf2 activator coumarin (27), and tBHQ is 
a derivative of the aromatic compound 
hydroquinone (28), which we identified in our 
screen. The identification of these known Nrf2 
activators corroborates the efficiency and 
suitability of the approach.  
Validation of the screening results using 
HaCaT keratinocytes – To validate the eight novel 
potential Nrf2 activators (hit compounds) we 
extended the reporter assays with HaCaT cells 
using different incubation times (5 h, 10 h or 24 h) 
and increasing concentrations of the compounds 
(0.1 µM, 10 µM, 25 µM and 50 µM). 
Furthermore, we tested the hit compounds on cells 
transfected with the pGL3-promoter vector 
(without ARE) to determine if the activation is 
indeed ARE-dependent. None of the eight 
compounds activated the reporter after transfection 
with this control vector, neither after 5 h or 10 h 
(data not shown) nor after 24 h (Fig.1A). By 
contrast, luciferase activity was strongly enhanced 
in cells transfected with the pGL3-8xARE-mGclm 
vector within 10 h (results not shown) and 24 h 
after addition of the compounds (Fig.1B), and the 
activation occurred in a dose-dependent manner. 
The strongest induction (5.5-fold) was achieved 
with 2-chloro-5-nitro-N-phenyl-benzamide 
(compound 1), followed by arecaidine propargyl 
ester hydrobromide (compound 2) and 4-phenyl-3-
furoxan-carbonitrile (compound 3). (Z)-
gugglesterone (compound 4), Bay 11-7085 
(compound 5), SKF 83959 hydrobromide 
(compound 6), spiperone hydrochloride 
(compound 7) and N-p-tosyl-L-phenylalanine 
chloromethyl ketone (compound 8) caused a 2 to 
3.5-fold increase in luciferase activity. For 
compounds 3, 4, 5 and 8 a dramatic reduction of 
reporter gene expression was observed with 
increasing concentrations, most likely reflecting 
cytotoxicity. Therefore, we used the concentration 
that induced the maximal activation for all further 
experiments.  
To determine if the hit compounds also 
activate gene expression via other AREs, we 
performed reporter assays with HaCaT cells 
transfected with the pGL3-1xARE-rNqo1 plasmid 
that contains the ARE and some additional 
flanking sequences from the promoter region of 
the rat Nqo1 gene. Indeed, all hit compounds also 
activated gene expression via this ARE in a dose-
dependent manner (Supplementary Fig.S2), and 
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compound 1 was again identified as the most 
potent inducer. Therefore, it seems likely that the 
compounds mediate gene expression via AREs 
and not via gene-specific flanking sequences. 
The hit compounds induce the expression of 
established Nrf2 target genes in HaCaT cells – We 
next determined if the hit compounds induce the 
expression of the known Nrf2 target genes GCLC, 
GCLM and NQO1 (29). For this purpose HaCaT 
cells were treated for 8 h, 24 h or 48 h with the hit 
compounds or with tBHQ or SFN as positive 
controls (Fig.2). Using quantitative Real-Time 
RT-PCR (qRT-PCR) we observed an increase in 
the mRNA levels of GCLC, GCLM and NQO1 
with most of the hit compounds. The time course 
of induction was target gene dependent. 
Compounds 1, 2, 3, 4 and 5 and to a lesser extent 
compound 8 induced the expression of all target 
genes, whereas only two of these genes were 
induced by compounds 6 and 7, and their effect 
was very mild. Taken together, six of the eight hit 
compounds efficiently induced the expression of 
Nrf2 target genes in HaCaT cells. 
The hit compounds act via Nrf2 – To 
determine if the activation of the previously tested 
cytoprotective genes by the hit compounds 
requires Nrf2, we tested their regulation in 
spontaneously immortalized keratinocytes isolated 
from Nrf2 knockout mice and their wild-type 
littermates. Lack of Nrf2 expression in cells from 
the knockout mice was verified by qRT-PCR (data 
not shown).  
Compounds 1, 2, 4 and 8 indeed induced the 
expression of Gclc, Gclm and Nqo1 in cells from 
wild-type mice, but not in cells from Nrf2 
knockout mice (Fig.3A-C). The only exception 
was compound 3, which also induced a mild 
upregulation of Gclm expression, indicating that 
this gene can also be regulated by other 
transcription factors in response to compound 3. 
Surprisingly, compound 5 was not able to induce 
the expression of Nrf2 target genes in murine 
keratinocytes. Similar to the results obtained with 
HaCaT cells, compounds 6 and 7 did not or only 
mildly activate Nrf2 target gene expression in 
murine keratinocytes.  Therefore, these 
compounds were not further characterized. 
Identification of additional Nrf2 activators by 
virtual screening based on the hit compounds – To 
identify additional and possibly improved Nrf2 
activators and to determine structural features that 
are important for Nrf2 activation, we selected six 
of the hit compounds (1-5, 8) as queries for ligand-
based virtual screening experiments (similarity 
searching) using the computational methods 
LIQUID (30) and PoLiMorph (31). We compiled a 
database comprising 1,033,267 commercially 
available compounds, which was screened using a 
consensus scoring scheme as described previously 
(32). We selected in total 20 compounds for in 
vitro testing (Table 2) from the six resulting hit 
lists. At least two compounds were chosen for 
each query. Their capability to activate Nrf2 in 
HaCaT cells using reporter gene assays with the 
pGL3-8xARE-mGclm construct was tested in 
three different concentrations (1 µM, 10 µM, 100 
µM). Six out of 20 test compounds (Table 2, 
highlighted in grey) increased reporter gene 
activity in three independent experiments by more 
than 1.5-fold. These included three analogues of 
compound 1 (1a-1c), a bioisoster of compound 2 
(2a), and two analogues of compound 5 (5a and 
5b) (Supplementary Table S3).  
Subsequently, we tested the ability of these six 
new compounds to induce the expression of the 
Nrf2 target gene Gclc in murine keratinocytes 
from wild-type mice (Fig.4A). Compounds 1c, 2a 
and 5b did not upregulate Gclc on the mRNA 
level (data not shown). However, compound 1b 
and in particular compound 1a caused a stronger 
increase in the expression of Gclc on the mRNA 
level compared to the original compound 1. 
Furthermore, treatment with compound 5a resulted 
in a higher upregulation of this Nrf2 target gene 
compared to the hit compound 5, although the 
overall activity of both compounds was low 
compared to the other, more active compounds. 
None of these compounds enhanced the expression 
of Gclc in keratinocytes lacking Nrf2.  
For the further characterization of the most 
interesting hit compounds (1, 2, 5) and their 
analogues (1a, 1b, 5a), in particular with regard to 
their potential future in vivo application, we used 
primary human foreskin keratinocytes (HFK). In 
general, the increase in the mRNA levels of the 
target gene GCLC was lower than in immortalized 
murine keratinocytes. Nevertheless, compounds 1, 
1a and 1b as well as 2 enhanced the expression of 
this gene in HFKs. Remarkably, compounds 1, 1a 
and 1b were even more potent than SFN in this 
assay. Since compounds 5 and 5a had no or only a 
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minor effect on GCLC expression (Fig.4B), we 
next focused our analysis on compounds 1 and 1a. 
Compounds 1 and 1a specifically activate 
ARE reporter genes. We first determined the 
specificity of compounds 1 and 1a with regard to 
reporter gene activation. For this purpose we 
tested if these compounds also activate reporter 
genes with response elements for unrelated 
transcription factors (NF-κB binding site, serum 
response element or cAMP response element). 
While these reporter genes were efficiently 
activated by TNF-α, serum or forskolin, 
respectively, compounds 1, 1a, sulforaphane and 
tBHQ did not activate these reporter genes at 
different concentrations (Supplementary Fig.S3). 
This result demonstrates the specificity of these 
compounds for AREs. 
        Compounds 1 and 1a activate Nrf2 in a 
PPARγ independent manner – Compound 1 (2-
chloro-5-nitro-N-phenyl-benzamide; GW9662) is 
a potent (IC50 in the nanomolar range) and 
irreversible antagonist of the peroxisome 
proliferator-activated receptor gamma (PPARγ) 
(33), a nuclear receptor transcription factor. 
PPARγ is expressed at low levels in human 
keratinocytes (34), which we confirmed for HFKs 
using qRT-PCR (data not shown). We next tested 
if modulation of PPARγ activity affects the 
activity of Nrf2. For this purpose we tested the 
effect of T0070907 and bisphenol A diglycidyl 
ether (BADGE), two other PPARγ antagonists (35, 
36), and of the PPARγ activator rosiglitazone (37), 
on GCLC and NQO1 gene expression in 
keratinocytes. Treatment with BADGE or 
rosiglitazone did not affect the expression of these 
Nrf2 target genes, whereas T0070909 treatment 
increased their expression (Fig.5). Compound 1 
and T0070907 are structurally related, whereas 
BADGE has a different structure (Supplementary 
Fig.S4). Since compound 1 and T0070907 bind 
covalently to cysteine residues of PPARγ (Cys285 
or Cys313, respectively) (33, 35), it seems likely 
that they activate Nrf2 through modification of 
cysteine residues in Keap1 rather than through 
inhibition of PPARγ activity. To test this 
hypothesis, we first treated recombinant human 
Keap1 with iodoacetamide under reducing 
conditions to identify the cysteines, which are 
accessible for covalent modification. Ten alkylated 
cysteine residues, including several which are 
modifiable by Nrf2 activating compounds (38), 
were modified under these conditions (data not 
shown). We then incubated recombinant full-
length human Keap1 protein with compound 1a 
and subsequently analyzed tryptic digests by mass 
spectrometry for cysteine containing peptides that 
had been covalently modified by the test 
compound. Indeed, we observed a stable 
modification by compound 1a of cysteine residue 
368 (Supplementary Fig.S5), a known highly 
reactive sensor cysteine in Keap1 (39), which 
could also be modified by iodoacetamide (see 
above). These findings strongly suggest that 
compound 1a activates Nrf2 via Keap1, but not 
via PPARγ. 
Compounds 1 and 1a reveal only low toxicity 
for primary human keratinocytes – We next 
analyzed the toxicity of compounds 1 and 1a for 
primary human keratinocytes. Remarkably, MTT 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra- 
zolium bromide) assays revealed a significantly 
lower toxicity of these compounds at higher 
concentrations compared to SFN and tBHQ 
(Fig.6A). This was confirmed by analysis of 
lactate dehydrogenase (LDH) activity in the cell 
supernatant (Fig.6B). The presence of this 
cytosolic enzyme in the medium reflects cell lysis. 
The discrepancy in the result obtained with SFN in 
the MTT and LDH assays may result from an 
interference of SFN with the LDH activity assay 
as suggested by the increase in the levels of β-
actin in the cell supernatant at high concentrations 
of SFN  (Supplementary Fig.S6A). To determine 
the effect of compounds 1 and 1a on ROS 
production, keratinocytes were treated with 2’,7’-
dichlorodihydrofluorescein diacetate (H2DCFDA) 
and subsequently analyzed for DCF fluorescence. 
Only a moderate ROS production was seen with 
both compounds, which was comparable to the 
production induced by SFN (Fig.6C). By contrast, 
ROS production was much higher in tBHQ- 
treated cells. The functionality of the assay was 
confirmed by analysis of cells treated with glucose 
oxidase (GO), which results in continuous 
production of hydrogen peroxide (Supplementary 
Fig.S6B).  
Compounds 1 and 1a protect keratinocytes 
from UVB-induced apoptosis - Since SFN protects 
keratinocytes in vitro and in vivo against UVB 
damage (18, 40), we tested if compounds 1 and 1a 
have a similar photoprotective potential. For this 
purpose, HFK were treated with Nrf2 activators 
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for different time periods (1 h, 4 h or 20 h) prior to 
irradiation with a physiological dose of UVB (50 
mJ/cm2). Remarkably, already a one-hour 
incubation with compounds 1 or 1a or with SFN 
reduced the LDH release compared to DMSO-
treated cells. The reduction was even stronger after 
a 20 h pre-treament, and cells treated with 
compounds 1 or 1a were more protected compared 
to SFN-treated cells (Fig.7A). The UVB-
protective effect of both compounds was verified 
by MTT assay, where pre-treatment with these 
compounds enhanced the viability of UVB-
irradiated keratinocytes (Fig.7B). These findings 
reveal that the novel Nrf2 activators identified in 
this study have a potent cytoprotective potential. 
 
DISCUSSION  
Activation of the cytoprotective transcription 
factor Nrf2 is a promising strategy for protection 
of cells under stress conditions. Nrf2 activation 
can be achieved by various low molecular weight 
compounds, of which some are in clinical trials for 
cancer prevention (41). Recently, novel Nrf2 
activators have been identified by screening of 
chemical libraries in cell culture assays (42-44). 
Of particular interest is a screen that used the 
LOPAC library (published by C. Klaassen in 
PubChem BioAssay, ID 624149). Surprisingly, 
there was only one overlap between this screen 
and our library screen – hydroquinone, a 
previously identified Nrf2 activator (see Results). 
By contrast, the new compounds that we identified 
are not included in the positive hits of this screen. 
These differences may result from the use of 
different cell lines (transformed breast cancer cell 
line versus non-transformed keratinocyte cell line). 
Importantly, none of the previously performed 
chemical library screens had been combined with 
a virtual screening approach. The latter represents 
an efficient strategy to identify novel compounds 
exhibiting a desired biochemical activity (45). In 
addition, UV-protective functions of these 
compounds have not been demonstrated. The 
possibility of using Nrf2 activators for cell 
protection under stress conditions is particularly 
promising for the skin, as demonstrated by the 
beneficial effect of sulforaphane for the treatment 
of skin blistering or protection from UV damage 
(40, 46, 47). However, sulforaphane has various 
Nrf2-independent effects (19, 20) and also induces 
pathological abnormalities in the skin upon long-
term application (21). Therefore, identification of 
novel and specific Nrf2 activators with low 
toxicity is highly desirable. Here we used a 
combination of chemical library screening and 
virtual screening to identify improved Nrf2 
activators in keratinocytes, which revealed low 
toxicity for keratinocytes combined with a potent 
cytoprotective potential. 
The chemical library screen identified six 
novel Nrf2 activators in keratinocytes. Compound 
4 ((Z)-gugglesterone) is a plant sterol for which 
multiple targets have been described, including 
several nuclear hormone receptors as well as IκB 
kinase (48, 49). Due to this broad activity 
spectrum, we decided not to further characterize 
this compound with regard to Nrf2 activation, in 
particular since none of the analogues revealed 
Nrf2 activating capacity. This was also the case 
for compound 3 (4-phenyl-3-furoxan-carbonitrile), 
which releases nitric oxide (NO) under the action 
of thiol co-factors, such as cysteines (50). NO was 
shown to cause (S)-nitrosation of cysteine residues 
in Keap1 and thereby activate Nrf2 (51, 52). Due 
to the cytotoxicity of NO, which was also reflected 
in the experiments with compound 3, the latter 
was also not further investigated. Obvious toxicity 
at higher concentrations was also observed for 
compound 8 (tosyl-L-phenyl-alanine chloro-
methyl ketone), and none of its analogues was able 
to activate Nrf2. Therefore, we decided to focus on 
the remaining three compounds. Among them, 
compound 1 and its derivatives appeared most 
interesting for the following reasons: (i) 
Compound 1 caused the strongest activation of the 
ARE reporter genes and of the endogenous Nrf2 
target genes; (ii) a class of structural analogues are 
functionally equivalent with regard to Nrf2 
activation, (iii) neither compound 1 nor its 
derivatives revealed obvious toxicity in the 
reporter assays and (iv) they are structurally 
unrelated to previously published Nrf2 activators. 
The difference between compounds 1 and 1a is a 
chinoline versus a phenyl group. Para-substituted 
nitrobenzene derivatives of 1 were active, while 
meta-substituents were not tolerated. Similarly, 
derivatives 5a and 5b indicate a critical region in 
the scaffold. This points to preliminary structure-
activity relationships that could be explored in 
future structure-based hit-to-lead optimization. 
The successful scaffold-hop (53) from compound 
2 to compound 2a is the most surprising finding 
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among the newly found actives. The quinuclidine 
2a features the tertiary nitrogen and a potential 
hydrogen-bond acceptor of the template 2, but 
offers alternative scaffold architecture. This 
example represents a pair of isofunctional 
chemotypes, with 2a being a second promising 
candidate, in addition to compound 1a, for further 
chemical exploration. 
The published target of compound 1 is PPARγ 
(33), which is irreversibly inhibited. However, it 
seems unlikely that inhibition of PPARγ is 
important for the effect on Nrf2, since a 
structurally unrelated PPARγ inhibitor did not 
activate Nrf2 target genes and since PPARγ 
activation also had no effect. Rather, it seems 
likely that compound 1 and its derivatives act via 
Keap1 due to the presence of reactive cysteines. 
Consistent with this hypothesis, mass spectrometry 
analysis of PPARγ modified by compound 1a had 
identified the cysteine residue 285 in the ligand 
binding site of PPARγ as the site of covalent 
modification (33). Using mass spectrometry we 
indeed identified direct binding of compound 1a to 
the highly reactive cysteine residue 368 in Keap1, 
suggesting that compound 1 and its analogues 
interact in a similar manner with Keap1 cysteine 
residues and thus activate Nrf2. 
A remarkable feature of these new Nrf2 
activators is the low toxicity for cultured 
keratinocytes, and both components were superior 
in this respect to SFN and tBHQ. Consistent with 
this finding, the capacity of compounds 1 and 1a 
to induce the production of ROS was lower 
compared to tBHQ, but similar to SFN. In spite of 
this reduced toxicity, the UVB-protective effect of 
our new compounds was similar or even higher 
compared to SFN. These findings strongly suggest 
that compounds 1 and 1a are interesting lead 
compounds for the development of drugs for skin 
protection under stress conditions. However, this 
will require establishment of an efficient in vivo 
delivery strategy. Thus, we only found a minor 
Nrf2-activating activity of compounds 1 and 1a in 
preliminary experiments, while SFN induced Nrf2 
target gene expression under the same conditions 
(data not shown). This is most likely due to 
inefficient penetration of compounds 1 and 1a 
through the epidermal barrier. Therefore, it will be 
important in the future to improve the topical 
delivery, either through chemical modification of 
the compounds or through use of alternative 
delivery vehicles. In addition, the consequences of 
long-term in vivo application of the compounds 
need to be determined, in particular with regard to 
potential skin sensitization. In spite of these open 
issues, our results demonstrate that library 
screening combined with ligand-based virtual 
screening is a potent strategy to identify novel 
Nrf2 activators. The latter are starting points for 
hit-to-lead optimization aiming at the development 
of drugs that can be used for skin protection in 
vivo.  
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Table 1. List of compounds that activated the luciferase reporter gene in at least two screening 
experiments. Additional information on the structure, targets and mechanisms of action of these 
compounds are provided in the description of the LOPAC library (Sigma) (PPARγ - peroxisome 
proliferator-activated receptor gamma, M2 receptor  - muscarinic acetylcholine receptor M2, NO - nitric 
oxide, FXR - farnesoid X receptor, IκBα - nuclear factor of κ light polypeptide gene enhancer in B-cells 
inhibitor α, D1/2 - dopamine receptor D1/D2, PDE - phosphodiesterase). 
 
 
 
Table 2. List of compounds identified in the virtual screen. Compounds, which increased reporter gene 
expression, are highlighted.   
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FIGURE LEGENDS 
 
Figure 1. Dose-dependent activation of luciferase activity by eight hit compounds. (A, B) HaCaT 
cells were transfected with the pGL3-promoter vector or with the pGL3-8xARE-mGclm reporter plasmid 
and treated for 24 h with different concentrations of the hit compounds as indicated or with 50 µM tBHQ 
or 5 µM SFN. Luciferase activities were determined in triplicates and normalized to luciferase activities 
seen in DMSO-treated cells. Bars represent mean of three independent experiments ±SD.  
 
Figure 2. Induction of Nrf2 target gene expression by treatment with the identified hit compounds. 
(A-C) HaCaT cells were treated for 8 h, 24 h or 48 h with tBHQ (50 µM), SFN (5 µM), or the different 
hit compounds. Compounds 3, 5, 6, 7 and 8 were used at a concentration of 10 µM, compounds 1 and 4 at 
a concentration of 25 µM and compound 2 at a concentration of 50 µM. RNA was isolated from the 
treated cells and analyzed for expression of the Nrf2 target genes GCLC, GCLM and NQO1 by qRT-PCR. 
RPL27 was used for normalization. The expression level in DMSO-treated HaCaT cells was set to 1. 
Values represent mean of three independent experiments ±SD.  
 
Figure 3. Hit compounds activate Nrf2 target genes in immortalized keratinocytes from wild-type 
but not from Nrf2 knockout mice (A-C) Spontaneously immortalized murine keratinocytes from wild-
type or Nrf2 knockout mice were treated for 8 h with tBHQ (50 µM), SFN (5 µM), or the hit compounds 
using the concentrations listed in the legend to Fig.2. RNA samples were analyzed for expression of the 
Nrf2 target genes Gclm, Gclc and Nqo1 by qRT-PCR. Rps29 was used for normalization. The expression 
levels in DMSO-treated keratinocytes of each genotype were set to 1. Bars represent mean of three 
independent experiments ±SD. 
  
Figure 4. Hit compounds and some of their analogues activate Gclc/GCLC in immortalized 
keratinocytes and in primary human foreskin keratinocytes. (A) Spontaneously immortalized murine 
keratinocytes from wild-type and Nrf2 knockout mice were treated for 8 h with tBHQ (50 µM), SFN (5 
µM), compounds 1 (25 µM), 1a (25 µM), 1b (25 µM), 2 (50 µM), 5 (10 µM) and 5a (10 µM). RNA 
samples were analyzed for expression of the Nrf2 target gene Gclc by qRT-PCR. Rps29 was used for 
normalization. The expression levels in DMSO-treated keratinocytes of each genotype were set to 1. (B) 
Primary human foreskin keratinocytes were treated for 24 h with tBHQ (50 µM), SFN (5 µM), 
compounds 1 (50 µM), 1a (50 µM), 1b (50 µM), 2 (50 µM), 5 (5 µM) and 5a (5 µM). RNA samples were 
analyzed for expression of the Nrf2 target gene GCLC by qRT-PCR. RPL27 was used for normalization. 
The expression levels in DMSO-treated keratinocytes were set to 1. Bars represent mean of three 
independent experiments ±SD.  
 
Figure 5. Upregulation of Nrf2 target genes by compounds 1 and 1a is not dependent on PPARγ 
inhibition. (A, B) Primary human foreskin keratinocytes were treated for 24 h with tBHQ (50 µM), SFN 
(5 µM), compounds 1 (50 µM), 1a (50 µM), BADGE (10 µM), T0070907 (10 µM) or rosiglitazone (10 
µM). RNA samples were analyzed for expression of GCLC and NQO1 by qRT-PCR. RPL27 was used for 
normalization. The expression level in DMSO-treated keratinocytes was set to 1. Bars represent mean of 
three independent experiments ±SD.   
 
Figure 6. Reduced toxicity of compounds 1 and 1a compared to tBHQ and sulforaphane. (A, B) 
Primary human foreskin keratinocytes were treated with tBHQ, SFN, compound 1 or compound 1a at 
different concentrations or with the solvent DMSO. Cell viability was determined after 24 h incubation 
using MTT assay (A) or by measurement of LDH activity in the cell supernatant (B). (C) Cells were 
treated with the solvent DMSO or with 5 µM SFN, 25 µM tBHQ, 50 µM compound 1 or 50 µM 
compound 1a and analyzed at different time points for the presence of intracellular ROS by DCF 
fluorescence measurement. Values from triplicate determinations are shown. Results shown in (A-C) 
were repeated in an independent experiment with a different batch of cells. 
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Figure 7. Compounds 1 and 1a protect keratinocytes from UVB toxicity. (A, B) Primary human 
foreskin keratinocytes were plated on 12-well plates and treated with DMSO, SFN (5 µM), compound 1 
(50 µM) or compound 1a (50 µM) for 1 h, 4 h or 20 h as indicated. After replacing the medium with fresh 
medium, cells were irradiated with a single dose of UVB  (50 mJ/cm2). Cytotoxicity was determined by 
LDH release (A). Bars represent mean of three independent experiments ±SD. Two-way ANOVA 
analysis showed significantly reduced LDH-release in cells pretreated with compounds 1 or 1a for 4 h or 
20 h when compared to vehicle control. Alternatively, cell viability was determined using MTT assay and 
analyzed in triplicate dishes (B). Results of a representative experiment out of four independent assays are 
shown.  
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